// App-Quantinova.ai

7019 : Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia.

Researchers

Presenter

  • Arran David Dokal

Principal Investigators

  • Andrea Arruda

  • Ryan Smith

  • Calum Greenhalgh

  • Francesca Patella

  • Pedro Maria Casado-Izquierdo

  • Bela Wrench

  • Jane Theaker

  • Andrew Thompson

  • Mark D. Minden

  • John G. Gribben

  • David James Britton

  • Pedro Rodriguez Cutillas

Medical Centers

  • Kinomica Limited, Macclesfield, United Kingdom

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Biohub Alderley Park, Macclesfield, United Kingdom

  • Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

  • Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Fms related tyrosine kinase 3

Drug/Treatment

  • Midostaurin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved